NextGen Targeted Therapy against Multiple Myeloma

Martin Döhring
vor 7 Stunden
2 Min. Lesezeit

Multiple Myeloma (MM) is one of the cancers where therapy has advanced dramatically in the past 15 years. The "most sophisticated" approaches now go far beyond chemotherapy or proteasome inhibitors — they involve precision immunotherapy, gene-engineering, and rational combinations.

Here’s the state-of-the-art therapeutic landscape, step by step:

1. The Traditional Backbone (Still Relevant)

Proteasome inhibitors (Bortezomib, Carfilzomib, Ixazomib): Exploit myeloma cells’ dependence on protein turnover.
IMiDs (Lenalidomide, Pomalidomide, Thalidomide): Modulate cereblon, leading to degradation of transcription factors (IKZF1/3) crucial for myeloma survival.
Monoclonal antibodies:
- Anti-CD38 (Daratumumab, Isatuximab): Kill via ADCC, CDC, apoptosis, and immune modulation.
- Anti-SLAMF7 (Elotuzumab): Activates NK cells against MM.

? These are combined in “triplets” or “quadruplets” (e.g., Dara-VRd = Daratumumab + Bortezomib + Lenalidomide + Dexamethasone).

2. Cellular Immunotherapies (Game-Changers)

(A) CAR-T cell therapy

Targets:
- BCMA (B-cell maturation antigen) — nearly universally expressed in MM.
- Examples: Idecabtagene vicleucel (Abecma, BMS/Bluebird Bio) and Ciltacabtagene autoleucel (Carvykti, Janssen/Legend).
Mechanism: Patient’s T cells are genetically engineered to express CARs recognizing BCMA → reinfused → directly kill myeloma cells.
Efficacy: Response rates >80%, many patients achieve minimal residual disease (MRD) negativity.
Challenges: Relapse due to antigen loss (BCMA downregulation), T cell exhaustion, or hostile bone marrow microenvironment.

(B) Allogeneic NK cell therapy / NK CARs

NK cells can be engineered (CAR-NK) to target MM (BCMA, SLAMF7, GPRC5D).
Advantage: “off-the-shelf” availability, lower risk of graft-versus-host disease.

3. Bispecific Antibodies (T-cell Redirectors)

Example: Teclistamab (Tecvayli), Elranatamab.
Mechanism: Bind BCMA on myeloma cells and CD3 on T cells → force synapse formation → direct cytotoxicity.
Advantages: Off-the-shelf, repeat dosing.
Expanding to other targets: GPRC5D (Talquetamab), FcRH5 (Cevostamab).
Some patients who relapse after CAR-T still respond to bispecifics.

4. Next-Generation Targeted Therapies

Cereblon E3 ligase modulators (CELMoDs): IBERDOMIDE, CC-92480 → stronger degradation of IKZF1/3 than lenalidomide.
Antibody-drug conjugates (ADCs):
- Belantamab mafodotin (Blenrep) → anti-BCMA linked to cytotoxic payload (MMAF).
Epigenetic modifiers (HDAC inhibitors like Panobinostat) — niche use.
Targeted signaling inhibitors (e.g., NF-κB, BCL-2 via Venetoclax in t(11;14) MM).

5. Combination & Sequential Strategies

The most sophisticated real-world therapy is not a single drug, but carefully sequencing and combining:

Newly diagnosed, fit patient: Dara-VRd induction → Autologous stem cell transplant → Dara-R maintenance.
Relapse 1: Switch classes (e.g., Carfilzomib + Anti-CD38 + Pomalidomide).
Heavily pretreated: CAR-T (Cilta-cel) or bispecifics (Teclistamab, Talquetamab).
Escape disease: Consider Venetoclax (for t(11;14)), CELMoDs, or trials with dual-target CAR-T (BCMA + GPRC5D).

6. “Most Sophisticated” Concept Right Now

The cutting edge is moving toward:

Dual-target CAR-T (BCMA + GPRC5D, to prevent antigen escape).
Allogeneic, off-the-shelf CAR-T/NK cells → no waiting time, scalable production.
Bispecific antibodies with switchable targets → continuous immune pressure.
Combination of CAR-T + bispecifics + CELMoDs → sustain remission.
Minimal residual disease (MRD)-guided therapy → stopping or intensifying based on real-time molecular disease monitoring.

✅ Summary:The most sophisticated therapy for multiple myeloma today is personalized immunotherapy targeting BCMA or alternative antigens, delivered either as CAR-T cells or bispecific antibodies, ideally integrated into a precision-medicine sequence (genetic profiling + MRD monitoring).This represents a shift from “controlling” MM to aiming for deep, durable, possibly curative remissions.